Medivir AB could earn about $111 million in up-front and milestone payments from two new drug development licensing deals with Tibotec Pharmaceuticals Ltd. (BioWorld International)

Unable To Attract Funding, TeGenero Going Belly Up

By Nuala Moran

Thursday, July 6, 2006

Buy Reprint

No Abstract

Nicotine Receptor Discovery Could Help Treat Addiction

By Sharon Kingman

Thursday, July 6, 2006

Buy Reprint

No Abstract

Diatos IPO Would Raise €25M, Sell Quarter Of Firm To Public

By James Etheridge

Thursday, July 6, 2006

Buy Reprint

No Abstract

Negative European Opinion Given For New Biogeneric

By Peter O'Donnell

Thursday, July 6, 2006

Buy Reprint

No Abstract

MediGene Shares Slide On FDA PDUFA Date Extension

By Cormac Sheridan

Thursday, July 6, 2006

Buy Reprint

No Abstract

BioWorld

Store

Others

BioWorld-International-2006-07-06

New Institute Being Built To Focus On Oxford Research

Vectura Gets £45M, Reports Trial Data For Two Products

Cellectis, Bayer CropScience Working On Plant Technology

Other News To Note

Medivir Could Earn $111M Through New Tibotec Deals

Unable To Attract Funding, TeGenero Going Belly Up

Nicotine Receptor Discovery Could Help Treat Addiction

Diatos IPO Would Raise €25M, Sell Quarter Of Firm To Public

Negative European Opinion Given For New Biogeneric

MediGene Shares Slide On FDA PDUFA Date Extension

Explore BioWorld.com

BioWorld

Store

Others

Login to Your Account

BioWorld

Store

Others

BioWorld-International-2006-07-06

Explore BioWorld.com

BioWorld

Store

Others